Publisher: Dānishgāh-i ʻUlūm-i Pizishkī-i Tihrān. Dānishkadah-ʼi Dārūʹsazī; SPARC (Organization), Tehran University of Medical Sciences

Journal description

Daru is a Persian name, meaning drug. Daru has been published in Persian from 1991 to 1995,in Persian with English abstract from 1995 to 1999 and only in English language form the early of 1999 four times a year. The main scope of this journal is to publish original research articles in pharmaceutical sciences. Editorial board of DARU are specialist in different areas of pharmacy. All submitted manuscripts are initially evaluated in the editorial meeting (regularly is held every two weeks) to determine peer reviewers in the related subjects. On the basis of reviewer's comments, the editorial committee decide about the acceptance or rejection of the submitted manuscript and in the case that the manuscript is acceptable, the main author will be asked to revise it according to the reviewer's comments or reply to their questions and comments. Final decision about acceptance of a manuscript for publication in DARU will be made in the editorial board meeting on the basis of reviewer's comments, author's responses or revisions. Outstanding basic and applied papers, reviews, short communication, and notes in the pharmaceutical and biomedical fields especially pharmaceutical and biomedical analyses, chemistry & medicinal chemistry, medical biotechnology, pharmaceutics, pharmacognosy & natural products, toxicology & pharmacology, clinical pharmacy & pharmacotherapy, quality control of foods and drugs, social aspects of pharmacy, and drug design are welcome. It is believed that there are only a few international journals that have the same general scope as DARU has. Scientists and academicians in the field of drug-related matters could be audience of this journal.

Current impact factor: 1.64

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 1.638
2013 Impact Factor 1.111
2012 Impact Factor 0.615
2011 Impact Factor 0.625
2010 Impact Factor 0.773
2009 Impact Factor 0.372
2008 Impact Factor 0.25
2007 Impact Factor 0.25

Impact factor over time

Impact factor

Additional details

5-year impact 1.43
Cited half-life 3.90
Immediacy index 0.32
Eigenfactor 0.00
Article influence 0.26
Website Daru website
Other titles Daru (Online), Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN 1560-8115
OCLC 61283828
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Tehran University of Medical Sciences

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Requested to link to publisher version
    • Publisher's version/PDF may be used
    • Creative Commons Attribution Non-Commercial 3.0 Unported License
    • All titles are open access journals
    • Publisher last contacted on 23/03/2012
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Sepsis complication is a major cause of death in multiple trauma critically ill patients. Defensin (cysteine rich anti-microbial peptides), as an important component of immune system, might play an important role in this process. There is also rising data on immunological effects of N-acetyl-cysteine (NAC), a commonly used anti-oxidant in oxidative stress conditions and glutathione (GSH) deficiencies. The aim of the present study was to evaluate the potential beneficial effects of NAC administration on multiple trauma patients with sepsis. Methods In a prospective, randomized controlled study, 44 multiple trauma critically ill patients who were mechanically ventilated and met the criteria of sepsis and admitted to the intensive care unit (ICU) were randomized into two groups . Control group received all standard ICU therapies and NAC group received intravenous NAC 3 gr every 6 hours for 72 hours in addition to standard therapies. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, length of ICU stay, ICU mortality were recorded. Levels of serum Immunoglobulin M (IgM), Human beta-Defensin 2 (HbetaD2) and GSH were assessed at baseline and 24, 72, 120 hours after intervention. Results During a period of 13-month screening, 44 patients underwent randomization but 5 patients had to be excluded. 21 patients in NAC group and 18 patients in control group completed the study. For both groups the length of ICU stay, SOFA score and systemic oxygenation were similar. Mortality rate (40% vs. 22% respectively, p = 0.209) and ventilator days (Mean +/- SD 19.82 +/- 19.55 days vs. 13.82 +/- 11.89 days respectively, p = 0.266) were slightly higher for NAC group. IgM and GSH levels were similar between two groups (p = 0.325, 0.125 respectively), HbetaD2 levels were higher for NAC group (at day 3). Conclusion High dose of NAC administration not only did not improve patients ' outcome, but also raised the risk of inflammation and was associated with increased serum creatinine.